Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its ...
A new study published in Advanced Science has revealed how curcumin, a bioactive compound found in Curcuma aromatica (Yujin), ...
How did the gas do this? By fine-tuning microglial activation to suppress pro-inflammatory cytokines and boost phagocytosis, according to the authors. These microglial changes depended on interferon-γ ...
Apigenin and Luteolin Modulate Microglial Activation Via Inhibition of STAT1-Induced CD40 Expression
Our previous research demonstrates that the CD40 signaling is critically involved in microglia-related immune responses in the brain. For example, it is well known that the activation of the ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Researchers have unveiled transformative insights into the relationship between inflammation and depression, a finding that ...
20d
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Scientists provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease. Their findings, based on studies in cell culture, mice and tissue ...
Scientists from DZNE, University Hospital Bonn (UKB) and the University of Bonn provide new evidence that preventing brain inflammation is a promising approach for the treatment of Alzheimer's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback